Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of “Buy” from Brokerages

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has earned an average rating of “Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $12.6250.

A number of research analysts recently issued reports on the company. Truist Financial set a $12.00 price objective on Perspective Therapeutics in a research report on Tuesday, March 17th. Piper Sandler assumed coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective for the company. HC Wainwright boosted their price objective on Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Wednesday, March 18th. Finally, B. Riley Financial boosted their price target on Perspective Therapeutics from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CATX. Vanguard Group Inc. raised its stake in shares of Perspective Therapeutics by 5.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after buying an additional 163,532 shares in the last quarter. Avidity Partners Management LP raised its stake in shares of Perspective Therapeutics by 7.2% in the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock worth $8,830,000 after buying an additional 216,700 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Perspective Therapeutics by 15.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after buying an additional 188,887 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Perspective Therapeutics in the 4th quarter worth $3,257,000. Finally, State Street Corp raised its stake in shares of Perspective Therapeutics by 3.3% in the 4th quarter. State Street Corp now owns 1,141,247 shares of the company’s stock worth $3,138,000 after buying an additional 36,543 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $4.25 on Wednesday. Perspective Therapeutics has a 12 month low of $1.75 and a 12 month high of $6.16. The company has a quick ratio of 5.17, a current ratio of 5.17 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average price of $4.81 and a two-hundred day moving average price of $3.56.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. The company had revenue of $0.04 million for the quarter. On average, equities analysts anticipate that Perspective Therapeutics will post -0.88 earnings per share for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.